On March 15, 2017,  the U.S. Food and Drug Administration (FDA) issued a drug safety communication for eluxadoline (also known by the brand name Viberzi), currently used in treating irritable bowel syndrome with diarrhea in adults, 18 and older, both men and women. This warning applies specifically to people without a gallbladder, whom the FDA advises

Rome IV International Diagnostic Criteria Updated in 2016 International functional GI experts finalized Rome IV, the first major update to the Rome criteria since 2006, in December 2014 in Rome, Italy. Rome IV was published in the journal Gastroenterology in May 2016 and officially presented to the gastroenterology professional community at the Digestive Disease Week